U.S. market Closed. Opens in 1 day 11 hours 11 minutes

PTCT | PTC Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 44.74 - 47.42
52 Week Range 23.58 - 54.16
Beta 0.67
Implied Volatility 78.18%
IV Rank 26.50%
Day's Volume 1,208,010
Average Volume 821,357
Shares Outstanding 77,125,100
Market Cap 3,566,264,624
Sector Healthcare
Industry Biotechnology
IPO Date 2013-06-20
Valuation
Profitability
Growth
Health
P/E Ratio -7.78
Forward P/E Ratio N/A
EPS -5.94
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 988
Country USA
Website PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
*Chart delayed
Analyzing fundamentals for PTCT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see PTCT Fundamentals page.

Watching at PTCT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on PTCT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙